Birdwatch Note
2024-11-05 10:21:37 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
投稿者は頻度の概念を無視しており、世界中のエビデンスに基づく専門機関の見解で下記のように評価されており、投稿は誤解を招くものです。 WHO コロナワクチンは安全。継続的に監視している。 重篤な副反応は極めて稀。 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice#:~:text=COVID%2D19%20vaccines%20are%20safe.&text=New%20versions%20of%20the%20vaccine,doses%20have%20been%20administered%20globally. 欧州EMA 重篤な副作用は起こるかもしれないが、とても稀で安全性プロファイルは良好。 https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines/safety-covid-19-vaccines#:~:text=The%20safety%20profiles%20of%20the,few%20of%20these%20rare%20cases. 米国 米国史上最も広範囲な安全性分析を受け、FDAの安全性と有効性の基準を満たしている(特定の同定済の重篤な疾患のリスクをあげつつ）。 https://www.cdc.gov/vaccine-safety/vaccines/covid-19.html 英国NHS コロナワクチンは厳格な安全性基準を満たしている。重篤な副作用は極めて稀。 https://www.nhs.uk/vaccinations/covid-19-vaccine/#:~:text=COVID%2D19%20vaccine%20safety,products%20Regulatory%20Agency%20(MHRA).
Written by 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1853709145045680275
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1853744469449007251
- noteId - 1853744469449007251
- participantId -
- noteAuthorParticipantId - 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE Participant Details
- createdAtMillis - 1730802097080
- tweetId - 1853709145045680275
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 投稿者は頻度の概念を無視しており、世界中のエビデンスに基づく専門機関の見解で下記のように評価されており、投稿は誤解を招くものです。 WHO コロナワクチンは安全。継続的に監視している。 重篤な副反応は極めて稀。 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice#:~:text=COVID%2D19%20vaccines%20are%20safe.&text=New%20versions%20of%20the%20vaccine,doses%20have%20been%20administered%20globally. 欧州EMA 重篤な副作用は起こるかもしれないが、とても稀で安全性プロファイルは良好。 https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines/safety-covid-19-vaccines#:~:text=The%20safety%20profiles%20of%20the,few%20of%20these%20rare%20cases. 米国 米国史上最も広範囲な安全性分析を受け、FDAの安全性と有効性の基準を満たしている(特定の同定済の重篤な疾患のリスクをあげつつ）。 https://www.cdc.gov/vaccine-safety/vaccines/covid-19.html 英国NHS コロナワクチンは厳格な安全性基準を満たしている。重篤な副作用は極めて稀。 https://www.nhs.uk/vaccinations/covid-19-vaccine/#:~:text=COVID%2D19%20vaccine%20safety,products%20Regulatory%20Agency%20(MHRA).
Note Ratings
| rated at | rated by | |
| 2024-11-05 19:21:00 -0600 | Rating Details | |
| 2024-11-05 18:45:35 -0600 | Rating Details | |
| 2024-11-05 17:45:00 -0600 | Rating Details | |
| 2024-11-05 16:57:41 -0600 | Rating Details | |
| 2024-11-05 16:24:32 -0600 | Rating Details | |
| 2024-11-05 16:11:38 -0600 | Rating Details | |
| 2024-11-05 15:23:23 -0600 | Rating Details | |
| 2024-11-05 10:38:06 -0600 | Rating Details | |
| 2024-11-05 08:15:41 -0600 | Rating Details | |
| 2024-11-05 08:00:24 -0600 | Rating Details | |
| 2024-11-05 07:54:38 -0600 | Rating Details | |
| 2024-11-05 07:52:59 -0600 | Rating Details | |
| 2024-11-05 07:51:27 -0600 | Rating Details | |
| 2024-11-05 07:44:24 -0600 | Rating Details | |
| 2024-11-05 07:25:02 -0600 | Rating Details | |
| 2024-11-05 07:11:33 -0600 | Rating Details | |
| 2024-11-05 06:33:49 -0600 | Rating Details | |
| 2024-11-05 06:17:51 -0600 | Rating Details | |
| 2024-11-05 06:16:39 -0600 | Rating Details | |
| 2024-11-05 06:03:42 -0600 | Rating Details | |
| 2024-11-05 05:49:46 -0600 | Rating Details | |
| 2024-11-05 05:48:31 -0600 | Rating Details | |
| 2024-11-05 05:40:47 -0600 | Rating Details | |
| 2024-11-05 05:36:06 -0600 | Rating Details | |
| 2024-11-05 05:32:38 -0600 | Rating Details | |
| 2024-11-05 05:32:29 -0600 | Rating Details | |
| 2024-11-05 05:27:12 -0600 | Rating Details | |
| 2024-11-05 05:15:07 -0600 | Rating Details | |
| 2024-11-05 05:13:45 -0600 | Rating Details | |
| 2024-11-05 05:12:13 -0600 | Rating Details | |
| 2024-11-05 05:08:38 -0600 | Rating Details | |
| 2024-11-05 05:07:25 -0600 | Rating Details | |
| 2024-11-05 04:58:56 -0600 | Rating Details | |
| 2024-11-05 04:57:45 -0600 | Rating Details | |
| 2024-11-05 04:54:07 -0600 | Rating Details | |
| 2024-11-05 04:53:59 -0600 | Rating Details | |
| 2024-11-05 04:53:09 -0600 | Rating Details | |
| 2024-11-05 04:49:47 -0600 | Rating Details | |
| 2024-11-05 04:46:03 -0600 | Rating Details | |
| 2024-11-05 04:45:35 -0600 | Rating Details | |
| 2024-11-05 04:35:32 -0600 | Rating Details | |
| 2024-11-05 04:35:30 -0600 | Rating Details | |
| 2024-11-05 04:33:12 -0600 | Rating Details | |
| 2024-11-05 04:29:02 -0600 | Rating Details | |
| 2024-11-05 04:28:46 -0600 | Rating Details | |
| 2024-11-05 04:25:08 -0600 | Rating Details | |
| 2024-11-07 08:58:33 -0600 | Rating Details | |
| 2024-11-05 17:11:26 -0600 | Rating Details | |
| 2024-11-05 08:36:05 -0600 | Rating Details | |
| 2024-11-05 07:34:18 -0600 | Rating Details | |
| 2024-11-05 07:17:13 -0600 | Rating Details | |
| 2024-11-05 06:56:28 -0600 | Rating Details | |
| 2024-11-05 06:55:16 -0600 | Rating Details | |
| 2024-11-05 06:40:49 -0600 | Rating Details | |
| 2024-11-05 06:14:49 -0600 | Rating Details | |
| 2024-11-05 06:12:10 -0600 | Rating Details | |
| 2024-11-05 05:55:48 -0600 | Rating Details | |
| 2024-11-05 05:35:23 -0600 | Rating Details | |
| 2024-11-05 05:32:18 -0600 | Rating Details | |
| 2024-11-05 05:31:14 -0600 | Rating Details | |
| 2024-11-05 04:57:38 -0600 | Rating Details | |
| 2024-11-05 04:53:26 -0600 | Rating Details | |
| 2024-11-05 04:32:10 -0600 | Rating Details | |
| 2024-11-05 04:29:32 -0600 | Rating Details | |
| 2024-11-12 17:15:30 -0600 | Rating Details | |
| 2024-11-05 23:45:49 -0600 | Rating Details | |
| 2024-11-05 15:55:11 -0600 | Rating Details | |
| 2024-11-05 11:38:34 -0600 | Rating Details | |
| 2024-11-05 07:25:29 -0600 | Rating Details | |
| 2024-11-05 07:14:49 -0600 | Rating Details | |
| 2024-11-05 06:17:27 -0600 | Rating Details | |
| 2024-11-05 06:09:58 -0600 | Rating Details | |
| 2024-11-05 06:04:42 -0600 | Rating Details | |
| 2024-11-05 05:56:32 -0600 | Rating Details | |
| 2024-11-05 05:01:56 -0600 | Rating Details | |
| 2024-11-05 05:01:27 -0600 | Rating Details | |
| 2024-11-05 04:59:37 -0600 | Rating Details | |
| 2024-11-05 04:56:00 -0600 | Rating Details | |
| 2024-11-05 04:46:14 -0600 | Rating Details | |
| 2024-11-05 04:40:07 -0600 | Rating Details | |
| 2024-11-05 04:36:31 -0600 | Rating Details | |
| 2024-11-05 04:31:24 -0600 | Rating Details | |
| 2024-11-05 04:26:35 -0600 | Rating Details |